IXC 1.41% 7.0¢ invex therapeutics ltd

Ann: Invex to close IIH Evolve Phase III Clinical Trial, page-39

  1. 1,365 Posts.
    lightbulb Created with Sketch. 280
    The raise of $20+ million post phase II trial, and Tattarang as a sub holder (along with Sinclair as a genuine leader in the field) did not scream red flags but obviously there was something there we all missed
    Last edited by BalkanBroker: 22/08/23
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
(20min delay)
Last
7.0¢
Change
-0.001(1.41%)
Mkt cap ! $5.261M
Open High Low Value Volume
7.1¢ 7.1¢ 7.0¢ $4.214K 59.36K

Buyers (Bids)

No. Vol. Price($)
1 198734 7.0¢
 

Sellers (Offers)

Price($) Vol. No.
7.6¢ 52542 1
View Market Depth
Last trade - 15.32pm 20/06/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.